Impact of obesity on factor VIII and von Willebrand factor levels in patients with Type 1 von Willebrand disease and low von Willebrand factor: An analysis of the ATHNdataset.
factor VIII
obesity
von Willebrand disease
von Willebrand factor Ristocetin cofactor activity
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
26
10
2021
received:
16
06
2021
accepted:
14
11
2021
pubmed:
8
12
2021
medline:
14
1
2022
entrez:
7
12
2021
Statut:
ppublish
Résumé
Obesity is associated with endothelial dysfunction, haemostatic and fibrinolytic disturbances, however the impact of obesity on von Willebrand factor (VWF) is unclear. The aim of this study was to test our hypothesis that the prevalence of obesity is higher among participants with low VWF (LVWF) compared to type 1 von Willebrand disease (T1VWD). A retrospective review of the ATHNdataset as of March 2018 was performed. Participants were categorized as T1VWD if their VWF ristocetin cofactor activity was 30 IU/dL and LVWF if the values were 30-50 IU/dL, and by the NIH definitions for body mass index (BMI) for adult participants (≥ 18 years of age) or BMI z-score for paediatric participants (< 18 years). The prevalence of obesity was not significantly different between adults with T1VWD (n = 186) and LVWF (n = 362) (32% vs 36%; p = .345). The mean factor VIII (FVIII) increased with increasing BMIs in both groups. In the paediatric cohort (T1VWD, n = 583; LVWF, n = 1702), there was no difference in the prevalence of obesity, but BMI was positively correlated with mean FVIII (p < .001). Children < 10 years were 27.6% more likely to be diagnosed with T1VWD compared to > 10 years. Among participants in the ATHNdataset, the prevalence of obesity was similar among those with LVWF and T1VWD. However, higher BMI levels were associated with elevated FVIII. Further research is needed to evaluate the impact of obesity on bleeding phenotype and treatment practices.
Substances chimiques
Hemostatics
0
von Willebrand Factor
0
Factor VIII
9001-27-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-116Subventions
Organisme : 2018 HTRS/ATHN DREAM Award from the Hemostasis and Thrombosis Research Society (HTRS) and the American Thrombosis and Hemostasis Network (ATHN), which was supported by Hemophilia of Georgia.
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Hales CMCM, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States: 2015-2016. NCHS Data brief. 2017. no 188(National Center for Health Statistics).
Atiq F, Fijnvandraat K, van Galen KPM, et al. BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. Am J Hematol. 2019;94(8):E201-e205.
Mertens I, Van der Planken M, Corthouts B, Van Gaal LF. Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?. Metab Clin Exp. 2006;55(5):650-655.
Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation. 2007;116(11):1234-1241.
Nightingale T, Cutler D. The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost. 2013;11(Suppl 1):192-201.
Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70(3):380-385.
Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. Transfusion. 2006;46(10):1836-1844.
Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol. 2006;60(2):144-151.
Abou-Ismail MY, Ogunbayo GO, Secic M, Kouides PA. Outgrowing the laboratory diagnosis of type 1 von Willebrand disease: a two decade study. Am J Hematol. 2018;93(2):232-237.
Borghi M, Guglielmini G, Mezzasoma AM, et al. Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?. Haematologica. 2017;102(11):e431-e433.
James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300.
Eikenboom JC, Castaman G, Kamphuisen PW, Rosendaal FR, Bertina RM. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost. 2002;87(2):252-257.
Hales CMCM, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: united States, 2017-2018. National Center for Health Statistics. 2020. NCHS Data Brief, no 360.
Wong TE, Majumdar S, Adams E, et al. Overweight and obesity in hemophilia: a systematic review of the literature. Am J Prev Med. 2011;41(6 Suppl 4):S369-375.
Branchford BR, Ruegg K, Villalobos-Menuey E, Jacobson LJ, Di Paola JA, Manco-Johnson M. FVIII/VWF ratio is not a reliable predictor of VWD in children. Pediatr Blood Cancer. 2014;61(5):936-939.
Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia. 2004;10(2):158-161.
Michael Soucie J, Miller CH, Byams VR, et al. Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia. 2021.
Srivaths L, Minard CG, O'Brien SH, et al. The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding. Blood Adv. 2020;4(13):3209-3216.
Sanders YV, Giezenaar MA, Laros-van Gorkom BA, et al. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost. 2014;12(7):1066-1075.
Sampson ME, Cheng D, Recht M, Fargo JH. The effect of age at diagnosis of type 1 von Willebrand disease on diagnostic laboratory values: a paediatric perspective. Haemophilia. 2021.
Atiq F, Meijer K, Eikenboom J, et al. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. Br J Haematol. 2018;182(1):93-105.
Seaman CD, Ragni MV. The effect of age on von Willebrand factor and bleeding symptoms in von Willebrand disease. Thromb Haemost. 2020;120(8):1159-1165.
Jaffray J, Staber JM, Malvar J, et al. Laboratory misdiagnosis of von Willebrand disease in post-menarchal females: a multi-center study. Am J Hematol. 2020;95(9):1022-1029.